The Company''s wholly owned subsidiary, Panacea Biotec Pharma Ltd. has received a Show Cause Notice (SCN) dated July 23, 2026, from the office of the Assistant Commissioner, Goods and Services ....

July 24, 2026 The Manager, Listing Department BSE Limited The National Stock Exchange of India Ltd. Corporate Relationship Department, Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (E), Mumbai - 400051 Dalal Street, Mumbai - 400001 NSE Symbol: PANACEABIO BSE Scrip Code: 531349 Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”) Dear Sir / Madam, Pursuant to Regulation 30 read with Para B of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”), we would like to inform you that the Company’s wholly owned subsidiary, Panacea Biotec Pharma Limited (“PBPL”), has received a Show Cause Notice dated July 23, 2026, from the office of the Assistant Commissioner, Goods and Services Tax (“GST”), Delhi under Section 73 of Delhi Goods & Services Tax / Central Goods & Services Tax Act & Rules, 2017 alleging total tax liability of ₹4.06 Crore including interest, tax and penalty, on account of alleged excess claim of Input Tax Credit in the Annual Return filed for the Financial Year 2022-23. The requisite details as required under Regulation 30 of the SEBI LODR Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, and Industry Standards on Regulation 30 of SEBI LODR Regulations, are annexed herewith as Annexure This is for your kind information and record please. Thanking you, Sincerely yours, For Panacea Biotec Limited Ankit Jain General Manager – Legal & Company Secretary Panacea Biotec Ltd (CIN: L33117PB1984PLC022350) Regd. Office : Ambala Chandigarh Highway, Lalru – 140501, Punjab Correspondence/Corporate office : B-1 Extn./G-3, Mohan Co-op. Indl. Estate, Mathura Road, New Delhi - 110 044, India Ph.: 91-11-4167 9000, 4167 8000, Fax: 91-11-4167 9070 Email: companysec@panaceabiotec.com Annexure A Details required under Regulation 30 of the SEBI LODR Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, and Industry Standards on Regulation 30 of SEBI LODR Regulations S. No. Particulars Details 1. N ame of the Listed Entity Panacea Biotec Limited 2. T ype of communication received The Company’s wholly owned subsidiary, Panacea Biotec Pharma Limited (“PBPL”) has received a Show Cause Notice (‘SCN’) dated 23.07.2026 from Assistant Commissioner, GST, Delhi under Section 73 of Delhi Goods & Services Tax / Central Goods & Services Tax Act & Rules, 2017 (“Act”) 3. D ate of receipt of communication 23.07.2026 4. A uthority from whom Assistant Commissioner, GST, Delhi communication received 5. B rief summary of the material SCN dated 23.07.2026 has been issued alleging total tax contents of the communication liability of ₹4.06 Crore (comprising of tax ₹2.27 Crore, received, including reasons for interest ₹1.56 Crore and penalty ₹0.23 Crore) on account of receipt of the communication inter-alia, excess claim of ITC. 6. P eriod for which communication Financial Year 2022-23 would be applicable, if stated 7. E xpected financial implications on PBPL is in the process of collating relevant details and the listed company, if any preparing draft reply against the notice received. PBPL does not foresee any adverse impact on its financial, operational, or other activities arising from this SCN. 8. D etails of any aberrations/non- The Authority has alleged claim of excess ITC compliances identified by the authority in the communication 9. D etails of any penalty or restriction Currently the matter is at SCN stage only. or sanction imposed pursuant to the communication 10. A ction(s) taken by listed company PBPL is in the process of preparing response against the with respect to the communication SCN. 11. A ny other relevant information Not Applicable Panacea Biotec Ltd (CIN: L33117PB1984PLC022350) Regd. Office : Ambala Chandigarh Highway, Lalru – 140501, Punjab Correspondence/Corporate office : B-1 Extn./G-3, Mohan Co-op. Indl. Estate, Mathura Road, New Delhi - 110 044, India Ph.: 91-11-4167 9000, 4167 8000, Fax: 91-11-4167 9070 Email: companysec@panaceabiotec.com